作者
Jorge Zimbron, Golam M Khandaker, Chiara Toschi, Peter B Jones, Emilio Fernandez-Egea
发表日期
2016/9/1
来源
European Neuropsychopharmacology
卷号
26
期号
9
页码范围
1353-1365
出版商
Elsevier
简介
Metabolic complications are commonly found in people treated with clozapine. Reviews on the management of this problem have generally drawn conclusions by grouping different types of studies involving patients treated with various different antipsychotics. We carried out a systematic review and meta-analysis of pharmacological and non-pharmacological treatments for clozapine-induced obesity or metabolic syndrome. Two researchers independently searched PubMed and Embase for randomised controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. All other types of studies were excluded. We only included RCTs where more than 50% of participants were taking clozapine.
We identified 15 RCTs. Effective pharmacological treatments for clozapine-induced obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in men only). Meta-analysis of three …
引用总数
2016201720182019202020212022202320244212589654